Icecure Medical Ltd Ord (ICCM)

$0.23 -0.01 (-4.13%)
Market Cap 19.48M
Revenue (ttm) 3.38M
Net Income (ttm) -15.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -445.56%
Debt to Equity Ratio 0.00
Volume 268,069
Avg Vol 645,334
Day's Range N/A - N/A
Shares Out 81.18M
Stochastic %K 12%
Beta 0.47
Analysts Strong Sell
Price Target $2.15

Company Profile

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel St., PO Box 3163, Caesarea, Israel
EarningsInsider
EarningsInsider May. 13 at 5:04 AM
https://www.marketbeat.com/earnings/reports/2026-5-12-icecure-medical-ltd-stock/ $ICCM IceCure Medical Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 1:34 PM
$ICCM Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.06 • Reported revenue of $0.91M up 25.66% YoY
0 · Reply
Zkoko_Bio
Zkoko_Bio May. 9 at 1:00 AM
$ICCM what a shit show...
3 · Reply
Bernperez
Bernperez May. 7 at 11:26 AM
$ICCM ICCM is about to do a RS.
0 · Reply
MomentumKiller
MomentumKiller May. 6 at 11:47 PM
$ICCM this thing should be through the roof by now!! Hopefully after the meeting more and more doctors use this treatment!!
0 · Reply
justme_DC
justme_DC May. 5 at 9:19 PM
$ICCM Only question in the near to mid term.....will they pump it shortly after the RS. If you are long and take offense to that....haha, you are probable not truly long if you are checking on these daily posts of forums
0 · Reply
Tonyboner
Tonyboner Apr. 30 at 8:33 PM
$ICCM Long time no seem, can I say something? "I TOLD YOU SO"
0 · Reply
Joe_088
Joe_088 Apr. 30 at 4:32 PM
$AKAN 👉 $ICCM
1 · Reply
Socaldodgerfan8
Socaldodgerfan8 Apr. 30 at 12:24 AM
$ICCM I never thought I’d see the day I moved all my money out of stocks into crypto. There are some really choice coins out there that have bottomed out, or very near bottom…which I believe presents lots of opportunities. At least for now, I no longer have to worry about RS’s or delistings. I’m out. I’m taking my ball and going home. I wish all of you good luck, and I hope you all make a bunch of money, or at least recoup your investment. I appreciate all of the guys (and girls) on this board for giving their honest insights and opinions.
0 · Reply
Logan93
Logan93 Apr. 28 at 5:56 PM
$ICCM just waiting for the bottom to fall out here.. if they pound it down to a nickel over the next two weeks, even a 30:1 isn’t going to do it much good 🤷‍♂️
0 · Reply
Latest News on ICCM
IceCure Medical reports Q1 EPS (6c) vs. (6c) last year

2026-05-12T15:06:32.000Z - 1 day ago

IceCure Medical reports Q1 EPS (6c) vs. (6c) last year

IceCure Medical Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 1 day ago

IceCure Medical Earnings Call Transcript: Q1 2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

May 12, 2026, 8:30 AM EDT - 1 day ago

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

May 6, 2026, 8:30 AM EDT - 7 days ago

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

May 5, 2026, 8:30 AM EDT - 8 days ago

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Medical initiated with a Buy at Alliance Global

2026-05-04T11:09:48.000Z - 9 days ago

IceCure Medical initiated with a Buy at Alliance Global

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

Apr 21, 2026, 8:30 AM EDT - 22 days ago

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Medical files to sell 16M ordinary share for holders

2026-04-01T20:36:41.000Z - 5 weeks ago

IceCure Medical files to sell 16M ordinary share for holders

IceCure Medical announces $4M registered direct offering

2026-03-26T12:12:30.000Z - 6 weeks ago

IceCure Medical announces $4M registered direct offering

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Medical reports results from clinical trial of ProSense for SRMs

2026-03-25T12:36:52.000Z - 7 weeks ago

IceCure Medical reports results from clinical trial of ProSense for SRMs

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

Mar 25, 2026, 8:30 AM EDT - 7 weeks ago

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Medical appoints Meir Peleg as CFO

2026-03-24T12:42:21.000Z - 7 weeks ago

IceCure Medical appoints Meir Peleg as CFO

IceCure Appoints Meir Peleg as Chief Financial Officer

Mar 24, 2026, 8:30 AM EDT - 7 weeks ago

IceCure Appoints Meir Peleg as Chief Financial Officer

IceCure Medical Earnings Call Transcript: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 2 months ago

IceCure Medical Earnings Call Transcript: Q4 2025

IceCure Medical reports FY25 EPS 24c vs 30c last year

2026-03-17T12:49:34.000Z - 2 months ago

IceCure Medical reports FY25 EPS 24c vs 30c last year

IceCure Reports 2025 Full Year Financial & Operational Results

Mar 17, 2026, 8:30 AM EDT - 2 months ago

IceCure Reports 2025 Full Year Financial & Operational Results

IceCure Medical receives FDA approval for ProSense study

2026-03-11T12:35:43.000Z - 2 months ago

IceCure Medical receives FDA approval for ProSense study

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Mar 11, 2026, 8:30 AM EDT - 2 months ago

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Mar 10, 2026, 8:30 AM EDT - 2 months ago

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

Mar 9, 2026, 8:30 AM EDT - 2 months ago

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

Mar 2, 2026, 8:30 AM EST - 2 months ago

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

IceCure Medical completes 5-year follow up study in kidney cancer cryoablation

2026-02-23T13:50:19.000Z - 2 months ago

IceCure Medical completes 5-year follow up study in kidney cancer cryoablation

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Feb 23, 2026, 8:30 AM EST - 2 months ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Feb 19, 2026, 8:30 AM EST - 2 months ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

Feb 11, 2026, 8:30 AM EST - 3 months ago

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

IceCure Medical announces departure of CFO Ronen Tsimerman

2026-02-09T21:35:34.000Z - 3 months ago

IceCure Medical announces departure of CFO Ronen Tsimerman

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Feb 9, 2026, 4:30 PM EST - 3 months ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 28, 2026, 8:30 AM EST - 3 months ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

IceCure Medical sees FY25 ProSense sales $3.4M

2026-01-12T13:51:33.000Z - 4 months ago

IceCure Medical sees FY25 ProSense sales $3.4M

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Jan 12, 2026, 8:30 AM EST - 4 months ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

IceCure Medical expects significant increase in Q4 sales in North America

2025-12-17T13:35:34.000Z - 5 months ago

IceCure Medical expects significant increase in Q4 sales in North America

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 17, 2025, 8:30 AM EST - 5 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 10, 2025, 8:30 AM EST - 5 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Medical receives Notice of Patent Allowance from CNIPA

2025-12-05T13:40:46.000Z - 5 months ago

IceCure Medical receives Notice of Patent Allowance from CNIPA

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Dec 5, 2025, 8:30 AM EST - 5 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Medical Earnings Call Transcript: Q3 2025

Nov 19, 2025, 10:00 AM EST - 6 months ago

IceCure Medical Earnings Call Transcript: Q3 2025

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 19, 2025, 8:54 AM EST - 6 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure Medical’s ProSense system receives regulatory approval in Switzerland

2025-11-18T14:42:02.000Z - 6 months ago

IceCure Medical’s ProSense system receives regulatory approval in Switzerland

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 18, 2025, 8:30 AM EST - 6 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical receives noncompliance notification from Nasdaq

2025-11-14T21:55:34.000Z - 6 months ago

IceCure Medical receives noncompliance notification from Nasdaq

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 6 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 6 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Medical names Shay Levav as COO

2025-11-10T13:36:31.000Z - 6 months ago

IceCure Medical names Shay Levav as COO

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 6 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 6 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright

2025-10-07T10:10:18.000Z - 7 months ago

IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright

IceCure Medical Transcript: Investor Update

Oct 6, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical Transcript: Investor Update

Icecure Medical Ltd trading resumes

2025-10-03T16:50:05.000Z - 7 months ago

Icecure Medical Ltd trading resumes

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 7 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation

2025-10-03T16:25:06.000Z - 7 months ago

IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 7 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Icecure Medical Ltd trading halted, news pending

2025-10-03T13:55:16.000Z - 7 months ago

Icecure Medical Ltd trading halted, news pending

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 8 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 8 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Medical Earnings Call Transcript: Q2 2025

Aug 13, 2025, 11:00 AM EDT - 9 months ago

IceCure Medical Earnings Call Transcript: Q2 2025

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 9 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 10 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 10 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 10 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 10 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 11 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 11 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 1 year ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Earnings Call Transcript: Q1 2025

May 28, 2025, 10:00 AM EDT - 1 year ago

IceCure Medical Earnings Call Transcript: Q1 2025

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 1 year ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 1 year ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 1 year ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 1 year ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

EarningsInsider
EarningsInsider May. 13 at 5:04 AM
https://www.marketbeat.com/earnings/reports/2026-5-12-icecure-medical-ltd-stock/ $ICCM IceCure Medical Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 1:34 PM
$ICCM Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.06 • Reported revenue of $0.91M up 25.66% YoY
0 · Reply
Zkoko_Bio
Zkoko_Bio May. 9 at 1:00 AM
$ICCM what a shit show...
3 · Reply
Bernperez
Bernperez May. 7 at 11:26 AM
$ICCM ICCM is about to do a RS.
0 · Reply
MomentumKiller
MomentumKiller May. 6 at 11:47 PM
$ICCM this thing should be through the roof by now!! Hopefully after the meeting more and more doctors use this treatment!!
0 · Reply
justme_DC
justme_DC May. 5 at 9:19 PM
$ICCM Only question in the near to mid term.....will they pump it shortly after the RS. If you are long and take offense to that....haha, you are probable not truly long if you are checking on these daily posts of forums
0 · Reply
Tonyboner
Tonyboner Apr. 30 at 8:33 PM
$ICCM Long time no seem, can I say something? "I TOLD YOU SO"
0 · Reply
Joe_088
Joe_088 Apr. 30 at 4:32 PM
$AKAN 👉 $ICCM
1 · Reply
Socaldodgerfan8
Socaldodgerfan8 Apr. 30 at 12:24 AM
$ICCM I never thought I’d see the day I moved all my money out of stocks into crypto. There are some really choice coins out there that have bottomed out, or very near bottom…which I believe presents lots of opportunities. At least for now, I no longer have to worry about RS’s or delistings. I’m out. I’m taking my ball and going home. I wish all of you good luck, and I hope you all make a bunch of money, or at least recoup your investment. I appreciate all of the guys (and girls) on this board for giving their honest insights and opinions.
0 · Reply
Logan93
Logan93 Apr. 28 at 5:56 PM
$ICCM just waiting for the bottom to fall out here.. if they pound it down to a nickel over the next two weeks, even a 30:1 isn’t going to do it much good 🤷‍♂️
0 · Reply
benof22
benof22 Apr. 26 at 5:57 AM
$ICCM Hail mary. But long term there is no way this company is not a success. The product is unique and if they can open it beyond the 70 age group then for sure even bigger succes. Im in it for the long term not short quick pay out
0 · Reply
UmmHmmDaddy
UmmHmmDaddy Apr. 24 at 6:13 PM
$ICCM scam company run by world class scammers
3 · Reply
Lstreak
Lstreak Apr. 24 at 1:46 PM
$ICCM This will probably fall close to a dime before R/S.
0 · Reply
Lstreak
Lstreak Apr. 24 at 1:43 PM
$ICCM IceCure Medical scheduled a May 11, 2026 remote special meeting to vote on a reverse share split. Shareholders will decide on authorizing a 10:1 to 30:1 reverse split, key for Nasdaq compliance and requiring active voting participation.
1 · Reply
Lstreak
Lstreak Apr. 24 at 1:42 PM
$ICCM https://www.tipranks.com/news/company-announcements/icecure-medical-calls-may-11-special-meeting-to-approve-potential-reverse-share-split
0 · Reply
Joe_088
Joe_088 Apr. 24 at 1:26 PM
$LNKS $IPW $ICCM $ELAB
0 · Reply
VikingTrade
VikingTrade Apr. 23 at 9:44 PM
$ICCM absolute clowns 🤡 running this company
0 · Reply
nvy
nvy Apr. 23 at 7:06 PM
$ICCM Had they released the 30%+ revenue growth without the March dilution, this may well have cleared $1. Not what they wanted. Instead dilute, solicit an extension, if it fails, imminent RS. No interest in shareholders, other than making money off of them. No insider buys even at depressed prices. Add to that the R&D VP left for greener pastures after 7 years.
0 · Reply
thechad369
thechad369 Apr. 23 at 2:36 PM
$ICCM no good, the sell off happens in 3 phases. Anticipation of RS, the RS itself, and then the offering following the RS, then your bottom is in
1 · Reply
grandpa_dirt
grandpa_dirt Apr. 23 at 2:16 PM
$ICCM https://www.tipranks.com/news/company-announcements/icecure-medical-calls-may-11-special-meeting-to-approve-potential-reverse-share-split I hope they go with the 30:1. With a 10:1 I doubt this stock could keep above 1.00 for more than a few days.
0 · Reply
Bernperez
Bernperez Apr. 23 at 10:08 AM
$ICCM Vla Dracula, lobbying to lower the age would target more people for the treatment and grow their market. Like I've said before, it's the idiots in charge!! Israeli's are very arrogant by nature and very stubborn and think they don't need help on running the company.
0 · Reply
Bernperez
Bernperez Apr. 23 at 9:51 AM
$ICCM They are holding a special shareholders and vote for a reverse stock split so they don't get delisted. This stock should be over $3. Prosense is a great treatment for cancer with great results. The problem is the idiots running this company. No market plan, no partnerships, no lobbying the right people. All of this should have been in place before FDA approvals. The revenue should be much higher by 10x. Like I said, it's the idiots in charge.
0 · Reply